 |
|
Phospho(Ser15)/Total HSP27 Base Kit
|
ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release.
Hua, F., Henstock, P.V., Tang, B.
|
Int Immunopharmacol. |
2010 |
|
A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients.
Singh, D., Smyth, L., Borrill, Z., Sweeney, L., Tal-Singer, R.
|
J Clin Pharmacol. |
2009 |
|
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.
Angell, R.M., Angell, T.D., Bamborough, P., Bamford, M.J., Chung, C.W., Cockerill, S.G., Flack, S.S., Jones K.L., Laine, D.I., Longstaff, T., Ludbrook, S., Pearson, R., Smith. K.J., Smee, P.A., Somers, D.O., Walker, A.L.
|
Bioorg Med Chem Lett |
2008 |
|
Analysis of mechanistic pathway models in drug discovery: p38 pathway.
Hendriks, B.S, Hua, F., Chabot, J.R.
|
Biotechnol Prog. |
2008 |
|
Safety, tolerability, pharmacokinetics, and pharmacodynamics of Losmapimod following a single intravenous or oral dose in healthy volunteers.
Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J.
|
Br J Clin Pharmacol. |
2012 |
|
|
|
|
 |
| Price |
Please call for price |
| Size |
20 plates |
| Catalog No. |
K15110A-3 |
| Availability |
Usually ships in 1-3 days |
|
Home
Products
K15110A-3
